2013 – 2015 Irish Cancer Society Research Fellow, Cancer Immunology, Prof Laurence Egan’s Research Group
2010 - 2012 Postdoctoral Researcher, Immunology Research Group, REMEDI, NUI, Galway
2006 - 2010 Postdoctoral Researcher, Discipline of Pharmacology & Therapeutics , NUIG
2005 - 2006 Postdoctoral Researcher, Department of Medicine, UCC & Cork University Hospital
Ph.D. in Medicine, University College Cork, Cork, Ireland
Understanding mechanisms of immune evasion in colon cancer with particular focus on the influence of tumor cell NF-kappaB activity on the microenvironment
The influence of NF-kappaB activity in colon tumor cells on macrophage polarization and sensitivity to apoptosis
Colon tumor cell and stromal cell interactions in the colon cancer microenvironment
My main research focus is in understanding the mechanisms by which tumor cells evade the anti-tumor immune response. More specifically, I focus on investigating the mechanisms by which tumor cell NF-κB activity and macrophages interact to regulate colon cancer metastasis. NF-κB can function both in the tumor cells, where it provides resistance to apoptosis and genotoxic insults, and in the immune compartment where its activation leads to the production of growth factors that can stimulate tumor growth.
O’Callaghan G, Ryan AE, Neary P, O’Mahoney K, Shanahan F, Houston AM.
2013 Targeting Fas Ligand increases the anti-tumor immune response in an in
vivo model of colon cancer. Int J Cancer; Feb 7. Epub ahead of print
Griffin MD, Ryan AE, Alagesan S, Lohan P, Treacy O, Ritter T. 2013. Anti-donor immune responses elicited by allogeneic Mesenchymal stem cells:what have we learned so far?. Immunology and Cell Biology Jan;91(1):40-51
Colleran A, Ryan AE, O’Gorman A, Mureau C, Liptrot C, Dockery P, Fearnhead H, Egan L. 2011 Autophagosomal IκBα degradation plays a role in the long term control of tumor necrosis factor-α-induced NF-κB activation. Journal of Biological Chemistry, Jul 1;286(26):22886-93.
O’Gorman A, Colleran A, Ryan AE, Mann J, Egan LJ. 2010. Regulation of NF-κB responses by epigenetic suppression of IκB-α expression in HCT116 intestinal epithelial cells. American Journal of Physiology GI and Liver. Jul; 299(1): G96-G105. Epub Apr 8.
Houston AM, Michael-Robinson JM, Walsh MD, Cunningham MC, Ryan AE, Lincoln D, Pandeya N, Jass JR, Radford-Smith GL, O'Connell J. 2008. The ‘Fas Counterattack’ is not an active mode of tumor immune evasion in colorectal cancer with high level microsatellite instability. Human Pathology, Feb; 39(2): 243-50.
Ryan AE, Lane S, Shanahan F, O'Connell J, Houston AM. 2006. Fas ligand expression in human and mouse cancer cell lines ; a caveat on over-reliance on mRNA data. Journal of Carcinogenesis. Feb 2: 5 (1):5
Ryan AE, Shanahan F, O'Connell J, Houston AM. 2006. Fas ligand promotes tumor immune evasion of colon cancer in vivo. Cell Cycle Feb 5(3) 246-9
Ryan AE, Shanahan F, O'Connell J, Houston AM. 2005. Addressing the Fas counterattack controversy: Blocking Fas ligand expression suppresses tumor immune evasion of colon cancer in vivo. Cancer Research 65: 9817-23